

**Correction to  
*Lancet Infect Dis* 2019;  
19: 802–03**

Garcia-Basteiro AL, Jenkins HE, Rangaka M. *The burden of latent multidrug-resistant tuberculosis.* *Lancet Infect Dis* 2019; **19**: 802–03—In this Comment, the terms “MDR disease” and “latent disease” have been replaced with “MDR tuberculosis infection” and “latent infection”, respectively, in several instances. The definition of multidrug resistance has also been updated to reflect that multidrug-resistant tuberculosis strains are resistant to both isoniazid and rifampicin. These changes have been made to the online version as of Aug 14, 2019.

**Correction to  
*Lancet Infect Dis* 2019;  
published online Aug 6.  
[https://doi.org/10.1016/  
S1473-3099\(19\)30310-X](https://doi.org/10.1016/S1473-3099(19)30310-X)**

Mullane KM, Morrison VA, Camacho LH, et al. *Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.* *Lancet Infect Dis* 2019; *published online Aug 6.* [https://doi.org/10.1016/S1473-3099\(19\)30310-X](https://doi.org/10.1016/S1473-3099(19)30310-X)—The appendix of this Article has been corrected as of Aug 23, 2019.



Published Online  
August 14, 2019  
[http://dx.doi.org/10.1016/  
S1473-3099\(19\)30443-8](http://dx.doi.org/10.1016/S1473-3099(19)30443-8)



Published Online  
August 23, 2019  
[http://dx.doi.org/10.1016/  
S1473-3099\(19\)30469-4](http://dx.doi.org/10.1016/S1473-3099(19)30469-4)